Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Veteran Stress and Learning Study (VSL)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
VA Office of Research and Development Identifier:
First received: May 6, 2008
Last updated: October 11, 2016
Last verified: October 2016
This is a research study examining the use of two medications, Hydrocortisone and D-Cycloserine, compared to an inactive substance (placebo), on their ability to reduce fear responses and memory of fear in Veterans with symptoms of Posttraumatic Stress Disorder (PTSD). These responses will be tested using a fear learning and memory task administered by computer.

Condition Intervention
Stress Disorders, Posttraumatic
Drug: Hydrocortisone
Drug: D-Cycloserine
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Effects of Hydrocortisone and D-Cycloserine on Fear Extinction in Veterans With Posttraumatic Stress Disorder

Resource links provided by NLM:

Further study details as provided by VA Office of Research and Development:

Primary Outcome Measures:
  • Skin Conductance [ Time Frame: Day 7, 9, 16 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Heart Rate [ Time Frame: Day 7, 9, 16 ] [ Designated as safety issue: No ]
  • Eye Blink [ Time Frame: Day 7, 9, 16 ] [ Designated as safety issue: No ]

Estimated Enrollment: 140
Study Start Date: July 2008
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1: Hydrocortisone
Drug: Hydrocortisone
25 mg/oral one hour prior to extinction task
Experimental: Arm 2: D-Cycloserine
Drug: D-Cycloserine
50 mg/oral one hour prior to extinction task
Placebo Comparator: Arm 3: Placebo
Drug: Placebo
One hour prior to extinction task


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Veterans and civilians with an age range of 18 to 65 years
  • Participants must be physically healthy volunteers

Exclusion Criteria:

  • Individuals who fall outside the age range
  • Individuals with medical conditions that would interfere with participation
  • Other criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00674570

United States, California
San Francisco VA Medical Center, San Francisco, CA
San Francisco, California, United States, 94121
Sponsors and Collaborators
VA Office of Research and Development
Principal Investigator: Sabra S Inslicht, PhD San Francisco VA Medical Center, San Francisco, CA
  More Information

Responsible Party: VA Office of Research and Development Identifier: NCT00674570     History of Changes
Other Study ID Numbers: H841-31915-01A 
Study First Received: May 6, 2008
Last Updated: October 11, 2016
Health Authority: United States: Federal Government
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by VA Office of Research and Development:
Stress Disorders, Posttraumatic
Extinction, Psychological
San Francisco

Additional relevant MeSH terms:
Stress Disorders, Traumatic
Stress Disorders, Post-Traumatic
Trauma and Stressor Related Disorders
Mental Disorders
Hydrocortisone 17-butyrate 21-propionate
Cortisol succinate
Hydrocortisone acetate
Anti-Inflammatory Agents
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Molecular Mechanisms of Pharmacological Action processed this record on October 21, 2016